Cargando…
Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116569/ https://www.ncbi.nlm.nih.gov/pubmed/35588736 http://dx.doi.org/10.1016/j.ccell.2022.05.003 |
| _version_ | 1784710140401811456 |
|---|---|
| author | Enssle, Julius C. Campe, Julia Büchel, Sarah Moter, Alina See, Frederic Grießbaum, Katharina Rieger, Michael A. Wolf, Sebastian Ballo, Olivier Steffen, Björn Serve, Hubert Rabenau, Holger F. Widera, Marek Bremm, Melanie Huenecke, Sabine Ciesek, Sandra von Metzler, Ivana Ullrich, Evelyn |
| author_facet | Enssle, Julius C. Campe, Julia Büchel, Sarah Moter, Alina See, Frederic Grießbaum, Katharina Rieger, Michael A. Wolf, Sebastian Ballo, Olivier Steffen, Björn Serve, Hubert Rabenau, Holger F. Widera, Marek Bremm, Melanie Huenecke, Sabine Ciesek, Sandra von Metzler, Ivana Ullrich, Evelyn |
| author_sort | Enssle, Julius C. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9116569 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-91165692022-05-19 Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma Enssle, Julius C. Campe, Julia Büchel, Sarah Moter, Alina See, Frederic Grießbaum, Katharina Rieger, Michael A. Wolf, Sebastian Ballo, Olivier Steffen, Björn Serve, Hubert Rabenau, Holger F. Widera, Marek Bremm, Melanie Huenecke, Sabine Ciesek, Sandra von Metzler, Ivana Ullrich, Evelyn Cancer Cell Letter Elsevier Inc. 2022-06-13 2022-05-08 /pmc/articles/PMC9116569/ /pubmed/35588736 http://dx.doi.org/10.1016/j.ccell.2022.05.003 Text en © 2022 Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter Enssle, Julius C. Campe, Julia Büchel, Sarah Moter, Alina See, Frederic Grießbaum, Katharina Rieger, Michael A. Wolf, Sebastian Ballo, Olivier Steffen, Björn Serve, Hubert Rabenau, Holger F. Widera, Marek Bremm, Melanie Huenecke, Sabine Ciesek, Sandra von Metzler, Ivana Ullrich, Evelyn Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma |
| title | Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma |
| title_full | Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma |
| title_fullStr | Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma |
| title_full_unstemmed | Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma |
| title_short | Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma |
| title_sort | enhanced but variant-dependent serological and cellular immune responses to third-dose bnt162b2 vaccination in patients with multiple myeloma |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116569/ https://www.ncbi.nlm.nih.gov/pubmed/35588736 http://dx.doi.org/10.1016/j.ccell.2022.05.003 |
| work_keys_str_mv | AT ensslejuliusc enhancedbutvariantdependentserologicalandcellularimmuneresponsestothirddosebnt162b2vaccinationinpatientswithmultiplemyeloma AT campejulia enhancedbutvariantdependentserologicalandcellularimmuneresponsestothirddosebnt162b2vaccinationinpatientswithmultiplemyeloma AT buchelsarah enhancedbutvariantdependentserologicalandcellularimmuneresponsestothirddosebnt162b2vaccinationinpatientswithmultiplemyeloma AT moteralina enhancedbutvariantdependentserologicalandcellularimmuneresponsestothirddosebnt162b2vaccinationinpatientswithmultiplemyeloma AT seefrederic enhancedbutvariantdependentserologicalandcellularimmuneresponsestothirddosebnt162b2vaccinationinpatientswithmultiplemyeloma AT grießbaumkatharina enhancedbutvariantdependentserologicalandcellularimmuneresponsestothirddosebnt162b2vaccinationinpatientswithmultiplemyeloma AT riegermichaela enhancedbutvariantdependentserologicalandcellularimmuneresponsestothirddosebnt162b2vaccinationinpatientswithmultiplemyeloma AT wolfsebastian enhancedbutvariantdependentserologicalandcellularimmuneresponsestothirddosebnt162b2vaccinationinpatientswithmultiplemyeloma AT balloolivier enhancedbutvariantdependentserologicalandcellularimmuneresponsestothirddosebnt162b2vaccinationinpatientswithmultiplemyeloma AT steffenbjorn enhancedbutvariantdependentserologicalandcellularimmuneresponsestothirddosebnt162b2vaccinationinpatientswithmultiplemyeloma AT servehubert enhancedbutvariantdependentserologicalandcellularimmuneresponsestothirddosebnt162b2vaccinationinpatientswithmultiplemyeloma AT rabenauholgerf enhancedbutvariantdependentserologicalandcellularimmuneresponsestothirddosebnt162b2vaccinationinpatientswithmultiplemyeloma AT wideramarek enhancedbutvariantdependentserologicalandcellularimmuneresponsestothirddosebnt162b2vaccinationinpatientswithmultiplemyeloma AT bremmmelanie enhancedbutvariantdependentserologicalandcellularimmuneresponsestothirddosebnt162b2vaccinationinpatientswithmultiplemyeloma AT hueneckesabine enhancedbutvariantdependentserologicalandcellularimmuneresponsestothirddosebnt162b2vaccinationinpatientswithmultiplemyeloma AT cieseksandra enhancedbutvariantdependentserologicalandcellularimmuneresponsestothirddosebnt162b2vaccinationinpatientswithmultiplemyeloma AT vonmetzlerivana enhancedbutvariantdependentserologicalandcellularimmuneresponsestothirddosebnt162b2vaccinationinpatientswithmultiplemyeloma AT ullrichevelyn enhancedbutvariantdependentserologicalandcellularimmuneresponsestothirddosebnt162b2vaccinationinpatientswithmultiplemyeloma |